Determining antibody status post-infection or post-vaccination
Serological immmunoassays are essential tools across multiple research disciplines: they are used to investigate previous pathogen exposures within populations as part of epidemiological studies, to understand the role of antibody responses in disease progression or to support the development of novel therapeutics and vaccines.
Multiplex immunoassays are a robust, high-content, high-throughput, antigen and sample-saving platform that provide a resource- and time-efficient alternative to classical assays such as ELISAs, while also increasing the amount of usable data gained from each measurement.
With over 20 years of experience, we specialize in the development of multiplex immunoassays for a variety of pathogens including RSV, hepatitis, and SARS-CoV-2. By using a multi-antigen and multi-pathogen approach, cross-reactive or cross-protective antibodies can also be evaluated.
An important research focus for us is the development of assays that allow us to distinguish between vaccine- and infection-related immune responses. The precise determination of these differences not only enables the accurate identification of a pathogen within a population, but can also be used to improve the performance of vaccines.